David Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York.
Edinburgh, UK, 5th December 2018 / Synpromics is pleased to hear that its partner, uniQure (NASDAQ:QURE), has announced the incorporation of its promoter, develope
Edinburgh, UK, 16th November 2018 / Synpromics, the leader in gene control, is delighted to announce that it has been ranked 12th in the
A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.
Sarah Haecker Meeks and David Venables enjoyed the sun in San Diego earlier this month for the annual ARM Cell & Gene Meeting on the Mesa.